进口与国产卡培他滨在结直肠癌化疗 XELOX方案中的成本-效果分析

目的：比较进口与国产卡培他滨在结直肠癌化疗XELOX方案中的成本-效果。方法：本文为前瞻性研究，选取79例采用卡培他滨+奥沙利铂（XELOX）方案化疗的肿瘤患者，将其分为两组（国产卡培他滨组和进口卡培他滨组）。观察6个化疗周期的疗效与药物成本，并运用药物经济学中的成本-效果分析法进行评价。结果与结论：国产卡培他滨（艾滨）组6个周期治疗有效率（80.8%）与进口卡培他滨（希罗达）接近（81.3%）。但是艾滨组6个周期的治疗成本为74 555.51元，显著性高于希罗达组（60 322.88元）。在药品不良反应方面，艾滨组高于希罗达组，有统计学差异（P<0.05）。成本-效果分析显示，在获得相同治疗效果的情况下，希罗达比艾滨更加经济。

Cost-effectiveness Analysis of Imported and Domestic Capecitabine in XELOX Chemotherapy Regimen for Colorectal Cancer

Objective: To evaluate the efficacy, costs and adverse reactions of imported and domestic capecitabine in XELOX chemotherapy for colorectal cancer by using cost-effectiveness analysis. Methods: Seventy-nine colorectal cancer patients receiving XELOX chemotherapy regimen for 6 cycles were divided into two groups: the imported capecitabine (Xeloda) group and the domestic capecitabine (AiBin) group. Data of curative efficacy, treatment costs and adverse reactions were collected and analyzed using the pharmacoeconomic cost-effectiveness analysis. Results and Conclusion: The objective response rates were comparable between the AiBin group and the Xeloda group (80.8% versus 81.3%, P=0.965). However, the treatment costs were significantly higher in AiBin group as compared to Xeloda group (74 555.51 versus 60 322.88, P<0.001). Furthermore, the rates of adverse reaction (including acid reflux, nausea, dizziness and numbness) were notably higher in the AiBin group than that in the Xeloda group (P<0.05). Cost-effectiveness analysis showed that Xeloda was more economical than AiBin.